Literature DB >> 489712

A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens.

C B Laurell, G Rannevik.   

Abstract

Analysis of 25 plasma proteins was performed on blood drawn from 7 females before and during treatment with danazol. This steroid was found to induce a pattern of plasma protein changes similar to but not identical with that of other 17 alpha-alkylated anabolic steroids. For comparison, the same 25 plasma proteins were analyzed in blood from pregnant women in their third trimester, when the estrogen influence on plasma protein synthesis is most pronounced. Five major types of response were found. 1) Albumin and orosomucoid were not influenced by danazol or, after correction for volume expansion, by pregnancy. 2) Prealbumin, C1-esterase inhibitor, and haptoglobins increased substantially during danazol treatment but were not significantly influenced by pregnancy. 3) Transferrin, antithrombin III, prothrombin, and plasminogen showed marked increases after administration of danazol and during pregnancy. 4) Transcortin, ceruloplasmin, and alpha 1-antitrypsin doubled in pregnancy but were not influenced by danazol. 5) The concentrations of T4-binding globulin, pregnancy zone protein, and sex hormone-binding globulin more than doubled in pregnancy, and all three decreased to one third or less on administration of danazol. The plasma estradiol content fell correspondingly. The different types of plasma protein response found in these two groups of patients fit the hypothesis that hepatocytes contain steroid receptors capable of reacting with estrogens and/or other steroids such as danazol and, thus, influence the biosynthetic rate of many but not all plasma proteins according to a specific pattern. The synthesis of some of the estrogen-sensitive proteins is depressed after intake of danazol, which suggests that there is a competition for the receptors in the hepatocytes as there is for other estrogen target tissues.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 489712     DOI: 10.1210/jcem-49-5-719

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Use of Estrogen-Containing Contraception Is Associated With Increased Concentrations of 25-Hydroxy Vitamin D.

Authors:  Quaker E Harmon; David M Umbach; Donna D Baird
Journal:  J Clin Endocrinol Metab       Date:  2016-08-04       Impact factor: 5.958

2.  Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin.

Authors:  J W Miller; A Skerjanec; M P Knadler; A Ghosh; S R Allerheiligen
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

3.  Impact of Menopause on Pharmacokinetics of Rosuvastatin Compared with Premenopausal Women.

Authors:  Shabnam Nazir; Zafar Iqbal; Fazli Nasir
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

4.  Estrogen in patients with prostatic cancer. An assessment of the risks and benefits.

Authors:  P Henriksson
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

5.  In utero copper treatment for Menkes disease associated with a severe ATP7A mutation.

Authors:  Marie Reine Haddad; Charles J Macri; Courtney S Holmes; David S Goldstein; Beryl E Jacobson; Jose A Centeno; Edwina J Popek; Willam A Gahl; Stephen G Kaler
Journal:  Mol Genet Metab       Date:  2012-05-18       Impact factor: 4.797

6.  The effects of 17 alpha-ethynyloestradiol and of acute inflammation on the plasma concentration of rat alpha 1-acid glycoprotein and on the induction of its hepatic mRNA.

Authors:  M Diarra-Mehrpour; J Bourguignon; I Leroux-Nicollet; D Marko-Vercaigne; D Biou; M Hiron; J P Lebreton
Journal:  Biochem J       Date:  1985-02-01       Impact factor: 3.857

7.  Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.

Authors:  James H Fischer; Gloria E Sarto; Jennifer Hardman; Loraine Endres; Thomas M Jenkins; Sarah J Kilpatrick; Hyunyoung Jeong; Stacie Geller; Kelly Deyo; Patricia A Fischer; Keith A Rodvold
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

8.  Serum high-sensitivity C-reactive protein as a biomarker in patients with metabolic syndrome: evidence-based study with 7284 subjects.

Authors:  S R Mirhafez; M Ebrahimi; M Saberi Karimian; A Avan; M Tayefi; A Heidari-Bakavoli; M R Parizadeh; M Moohebati; M R Azarpazhooh; H Esmaily; M Nematy; M Safarian; G A Ferns; M Ghayour-Mobarhan
Journal:  Eur J Clin Nutr       Date:  2016-07-27       Impact factor: 4.016

Review 9.  The effects of drugs on tests of thyroid function.

Authors:  P H Davies; J A Franklyn
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Fucosylated forms of alpha-1-antitrypsin that predict unresponsiveness to chemotherapy in ovarian cancer.

Authors:  S Thompson; D Guthrie; G A Turner
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.